Thymol iodide

  • Annidalin
  • 5,5'-Diisopropyl-2,2'-dimethylbiphenyl-4,4'-diyl dihypoiodite
  • 4,4'-bis(Iodooxy)-2,2'-dimethyl-5,5'-bis(1-methylethyl-1,1'-Biphenyl
  • Bithymol diiodide
  • Diiododithymol
  • Dithymol diiodide
Formula
C20H24I2O2
Structure
Description
Reddish-brown or reddish-yellow bulky powder. Slight aromatic odor.
Uses
Medication: antifungal, anti-infective agent, medication (vet): has been used externally as antiseptic.

Registry Numbers and Inventories.
CAS
552-22-7
EC (EINECS/ELINCS)
209-007-5
Beilstein/Gmelin
NA
Canada DSL/NDSL
DSL
US TSCA
Listed
Austrailia AICS
Listed
New Zealand
Listed

Properties.
Formula
C20H24I2O2
Formula mass
550.22
Solubility in water
Insoluble

Hazards and Protection.
Storage
Keep product out of light and container tightly closed. Suitable for any general chemical storage area.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Dust mask.
Small spills/leaks
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stability
Stable at normal temperatures and pressures.
Incompatibilities
Strong oxidizing agents.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Exposure effects
Abnormally low blood pressure, reduced body temperature, rapid breathing, and rapid heart rate may develop with severe toxicity. Initial CNS excitation, including seizures, is commonly followed by CNS depression ranging from lethargy to coma and death. Fetotoxicity and skeletal abnormalities have been reported in animal experiments.
   Ingestion
Phenol is extremely corrosive and may cause oral and esophageal burns and abdominal pain following ingestion.
   Inhalation
Tachypnea is commonly reported; pulmonary edema and bronchospasm may also occur. Stridor has been reported from exposure to high concentrations of phenol. Respiratory arrest occurred 30 minutes post ingestion of 26.7 Grams of phenol in one case.
   Skin
Phenol is corrosive to the skin, but because of anesthetic qualities, it will numb rather than causing a burning pain on contact. Skin becomes red and swollen, then white and opaque. Deep burns result that may become gangrenous.
   Eyes
A metallic taste, increased salivary and bronchial secretions may be noted.

First aid
 
   Ingestion
Dilution - may enhance absorption of phenol, and should be avoided. Emesis: ipecac-induced vomiting is not recommended because of the potential for cns depression and seizures. Activated charcoal - may limit systemic toxicity if administered soon after ingestion, but may interfere with endoscopic evaluation of gastrointestinal burns.
   Inhalation
Move patient to fresh air. Monitor for respiratory distress. If cough or difficulty breathing develops, evaluate for respiratory tract irritation, bronchitis, or pneumonitis. Administer oxygen and assist ventilation as required. Treat bronchospasm with beta2 agonist and corticosteroid aerosols.
   Skin
Remove phenol with undiluted polyethylene glycol 300 to 400 or isopropyl alcohol prior to washing, if readily available. Wash exposed areas twice with large quantities of water. A physician may need to examine the exposed area if irritation or pain persist after the area is washed.
   Eyes
Irrigate exposed eyes with copious amounts of tepid water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist, the patient should be seen in a health care facility.

Transport.